Boston Scientific (NYSE:BSX) Sets New 1-Year Low – Should You Sell?

Boston Scientific Corporation (NYSE:BSX) shares hit a new 52-week low during trading on Monday . The stock traded as low as $53.26 and last traded at $53.3350, with a volume of 643182 shares changing hands. The stock had previously closed at $53.93.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on BSX. UBS Group decreased their price objective on Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a report on Tuesday, March 17th. Stifel Nicolaus decreased their price objective on Boston Scientific from $90.00 to $85.00 and set a “buy” rating for the company in a report on Tuesday, April 21st. Jefferies Financial Group decreased their price objective on Boston Scientific from $110.00 to $100.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. BTIG Research decreased their price objective on Boston Scientific from $90.00 to $80.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. Finally, Wells Fargo & Company decreased their price objective on Boston Scientific from $94.00 to $75.00 and set an “overweight” rating for the company in a report on Thursday, April 23rd. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $93.91.

Boston Scientific Price Performance

The company has a market cap of $80.43 billion, a PE ratio of 22.64, a price-to-earnings-growth ratio of 0.98 and a beta of 0.62. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The stock has a 50 day moving average of $64.65 and a 200-day moving average of $82.68.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The company had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter last year, the business posted $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts predict that Boston Scientific Corporation will post 3.38 earnings per share for the current year.

Hedge Funds Weigh In On Boston Scientific

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BSX. Norges Bank acquired a new stake in Boston Scientific during the 4th quarter worth about $2,199,395,000. Assenagon Asset Management S.A. grew its position in Boston Scientific by 133.6% during the 1st quarter. Assenagon Asset Management S.A. now owns 10,057,936 shares of the medical equipment provider’s stock worth $631,135,000 after purchasing an additional 5,751,760 shares during the period. Egerton Capital UK LLP grew its position in Boston Scientific by 223.7% during the 3rd quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock worth $518,660,000 after purchasing an additional 3,671,548 shares during the period. Maverick Capital Ltd. acquired a new stake in Boston Scientific during the 4th quarter worth about $280,735,000. Finally, Jennison Associates LLC grew its position in Boston Scientific by 133.5% during the 3rd quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider’s stock worth $482,170,000 after purchasing an additional 2,823,744 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.